

Farxiga® (dapagliflozin) – New indication

- On April 30, 2021, the [FDA announced](#) the approval of [AstraZeneca’s Farxiga \(dapagliflozin\)](#), to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease (ESKD), cardiovascular (CV) death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression.
 - Farxiga is not recommended for the treatment of CKD in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. Farxiga is not expected to be effective in these populations.
- Farxiga is also approved:
 - As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).
 - To reduce the risk of hospitalization for heart failure in adults with T2DM and either established CV disease or multiple CV risk factors.
 - To reduce the risk of CV death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction.
- Farxiga is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved for the treatment of CKD regardless of diabetes status.
- The approval of Farxiga for the new indication was based on the DAPA-CKD trial, a randomized, double-blind, placebo-controlled study in 4,304 patients with CKD stages 2 to 4 and albuminuria. Patients received Farxiga or placebo, in addition to standard of care background therapy. The primary composite endpoint was worsening of renal function or risk of death (defined as a composite of an eGFR decline $\geq 50\%$, onset of ESKD, or death from CV or renal cause).
 - At least one composite endpoint event occurred in 197 of the 2,152 patients who received Farxiga vs. 312 of the 2,152 patients who received placebo (hazard ratio [HR] 0.61, 95% CI: 0.51, 0.72; $p < 0.0001$).
 - All-cause mortality occurred in 101 patients who received Farxiga vs. 146 patients who received placebo (HR 0.69, 95% CI: 0.53, 0.88; $p = 0.0035$).
- The recommended dose of Farxiga is based on eGFR level.

eGFR (mL/min/1.73 m ²)	Dosing frequency
eGFR 45 or greater	To improve glycemic control, the recommended starting dose is 5 mg orally once daily. Dose can be increased to 10 mg orally once daily for additional glycemic control*.

	For all other indications, the recommended starting dose is 10 mg orally once daily.
eGFR 25 to less than 45	10 mg orally once daily*.
eGFR less than 25	Initiation is not recommended; however, patients may continue 10 mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hospitalization for heart failure.
On dialysis	Contraindicated.

*Farxiga is not recommended for use to improve glycemic control in adults with T2DM with an eGFR less than 45 mL/min/1.73 m². Farxiga is likely to be ineffective in this setting based upon its mechanism of action.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.